This study is currently not recruiting participants.

Use of FibroScan? with Controlled Attenuation Parameter to Estimate the Prevalence of NAFLD with Advanced Fibrosis in Patients with or without Metabolic Syndrome

  • STATUS
    Not Recruiting
Updated on 19 February 2024

Summary

The purpose of this study are to prospectively estimate the prevalence of NAFLD with or without advanced fibrosis in patients with or without metabolic syndrome using FibroScan? with CAP and to examine the relationship between hepatic steatosis measured using CAP and steatosis graded by liver histology and with actual measurement of hepatic triglyceride content in patients where liver histology is available.

Description

The purpose of this study are to prospectively estimate the prevalence of NAFLD with or without advanced fibrosis in patients with or without metabolic syndrome using FibroScan? with CAP and to examine the relationship between hepatic steatosis measured using CAP and steatosis graded by liver histology and with actual measurement of hepatic triglyceride content in patients where liver histology is available.

Details
Condition NAFLD
Age 100years or below
Clinical Study IdentifierTX6593
Last Modified on19 February 2024

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.